Cargando…

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

BACKGROUND: Plasmacytoid urothelial carcinoma (PUC) is a rare, aggressive histologic variant of urothelial cancer characterised by a diffuse growth pattern and CDH1 mutation. We studied the efficacy of preoperative platinum-based chemotherapy in nonmetastatic PUC and immune checkpoint inhibitors (IC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, Rosenberg, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007750/ https://www.ncbi.nlm.nih.gov/pubmed/33473164 http://dx.doi.org/10.1038/s41416-020-01244-2

Ejemplares similares

“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
por: Pietzak, Eugene J., et al.
Publicado: (2019)

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer
por: Clinton, Timothy N., et al.
Publicado: (2022)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
por: Damrauer, Jeffrey S., et al.
Publicado: (2021)

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
por: Pietzak, Eugene J., et al.
Publicado: (2022)

Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
por: Donahue, Timothy F., et al.
Publicado: (2018)

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
por: Bazzi, Wassim M., et al.
Publicado: (2014)

Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile
por: Simon, Caroline T., et al.
Publicado: (2019)

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
por: Holm, Jeppe Sejerø, et al.
Publicado: (2022)

The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum
por: Liu, Nick W., et al.
Publicado: (2019)

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
por: Kim, Kwanghee, et al.
Publicado: (2020)

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)
por: Dalbagni, Guido, et al.
Publicado: (2017)

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
por: Abida, Wassim, et al.
Publicado: (2016)

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
por: Snyder, Alexandra, et al.
Publicado: (2017)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
por: Katims, Andrew B., et al.
Publicado: (2022)

Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
por: Warrick, Joshua I., et al.
Publicado: (2022)

FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
por: Warrick, Joshua I., et al.
Publicado: (2022)

Plasmacytoid urothelial carcinoma of the bladder: a case report
por: Aldousari, Saad, et al.
Publicado: (2009)

Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2022)

Id Proteins Contribute to Tumor Development and Metastatic Colonization in a Model of Bladder Carcinogenesis
por: Garcia-Cao, Marta, et al.
Publicado: (2015)

Isolated cardiac metastasis from plasmacytoid urothelial carcinoma of the bladder
por: Peck, Joshua R, et al.
Publicado: (2012)

Plasmacytoid variant of urothelial carcinoma: Diagnostic challenges and role of immunohistochemistry
por: Jairajpuri, Zeeba S., et al.
Publicado: (2015)

Plasmacytoid urothelial carcinoma of the bladder with extensive scrotal wall invasion
por: Wang, Yong Gang, et al.
Publicado: (2016)

Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma
por: Lockhart, Kathleen, et al.
Publicado: (2021)

The patient’s perspective on blue light flexible cystoscopy: insight from a prospective clinical study
por: Almassi, Nima, et al.
Publicado: (2018)

Urethral Melanoma – Clinical, Pathological and Molecular Characteristics
por: Mano, Roy, et al.
Publicado: (2022)

Plasmacytoid Urothelial Carcinoma of the Bladder Metastatic to the Stomach: A Case Report
por: Nabbout, Philippe, et al.
Publicado: (2012)

Plasmacytoid Urothelial Carcinoma of Ureter with Retroperitoneal Metastasis: A Case Report
por: Jibril, Alexis, et al.
Publicado: (2018)

Advancements in Laparoscopic Partial Nephrectomy: Expanding the Feasibility of Nephron-Sparing
por: Pietzak, Eugene J., et al.
Publicado: (2012)

A Case of Urinary Bladder Urothelial Carcinoma with Squamous, Glandular, and Plasmacytoid Differentiation
por: Makise, Naohiro, et al.
Publicado: (2014)

Is ‘second-look’ (re-staging) transurethral resection of bladder tumours a new standard of care?
por: Herr, Harry, et al.
Publicado: (2011)

The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery
por: Morganstern, Bradley Andrew, et al.
Publicado: (2011)

A rare case of plasmacytoid urothelial carcinoma of bladder: Diagnostic dilemmas and clinical implications
por: Rahman, Khaliqur, et al.
Publicado: (2011)

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
por: Kim, Bohyun, et al.
Publicado: (2016)

Plasmacytoid variant of urothelial carcinoma of the bladder manifesting as bilateral ureteral and small bowel obstruction
por: Carsel, Alex, et al.
Publicado: (2020)

Expression of epithelial-Mesenchymal transition related markers in Plasmacytoid Urothelial carcinoma of the urinary bladder
por: Nomura, Shunichiro, et al.
Publicado: (2020)

Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2014)

Multiparametric magnetic resonance imaging of plasmacytoid urothelial carcinoma with histopathological correlation: A case report
por: Ito, Koichi, et al.
Publicado: (2022)

Metastatic Plasmacytoid Urothelial Carcinoma Masquerading as a Primary Signet Ring Cell Carcinoma of the Duodenum
por: Mir, Adil S, et al.
Publicado: (2023)

Macrophage activity at the site of tumor ablation can promote murine urothelial cancer via transforming growth factor-β1
por: Kimura, Yasushi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gkag4rug97siva49vta7dulchc